_1579501833221.png?format=webp&height=120&width=120){kind=logo}
About Panacea Venture
Panacea Venture is a venture capital firm founded in 2017. It is primarily based out of Xuhui, China. As of Jun 2025, Panacea Venture is an active investor, having invested in 40 companies, with 1 new investment in the last 12 months. It primarily invests in Seed round in China based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Seed round of OutSee Overall, Panacea Venture portfolio has seen 4 IPOs including key companies like Kindstar, Windtree Therapeutics and Zhaoke Ophthalmology. A lot of funds co-invest with Panacea Venture, with names like Korea Investment Holdings sharing a substantial percentage of its portfolio. Panacea Venture has team of 24 people including 12 partners.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Seed, Series A & 4 more
Portfolio IPOs
Portfolio Soonicorns
Deals in last 12 months
Panacea Venture's List of Top Investments
Panacea Venture has a portfolio of 40 companies. Their most notable investments are in OncXerna and Actym Therapeutics.Their portfolio spans across China, United States, United Kingdom and 2 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 2 other sectors, across stages such as Seed, Series A and 4 more. Here is the list of top investments by Panacea Venture:
Provider of precision medicine, preventative health assessments, and longevity care. The company offers comprehensive health assessments to detect life-threatening conditions early. It focuses on data-driven, personalized healthcare designed to uncover health risks. The company provides services to help individuals take control of their health.
Key facts about Human Longevity
- Founded Year: 2013
- Location: San Diego (United States)
- Valuation: $*****
- Stage: Series B
- Total Funding till date: $409M
- Employee Count: 81 as on Jan 31, 2026
- Investors: Celgene, General Electric and 20 Others
- Latest Funding Round: Series B, Aug 21, 2024, $*****
- Highlight: Editors' Pick
Developer of exosome-based therapies for neurological diseases. It uses a proprietary CRISPR/Cas-based gene editing system encapsulated within exosomes to target and modify genes responsible for neurodegenerative and neurological conditions. The pipeline includes therapeutic candidates targeting the ATXN2 gene, the primary genetic driver of Spinocerebellar Ataxia type 2 and a significant disease modifier in Amyotrophic Lateral Sclerosis. It also has a therapeutic candidate targeting the MSH3 gene for Huntington’s disease and other related triplet repeat expansion disorders.
Key facts about Evox Therapeutics
- Founded Year: 2016
- Location: Oxford (United Kingdom)
- Annual Revenue: £9.22M as on Dec 31, 2023
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $156M
- Employee Count: 45 as on Jan 31, 2026
- Investors: Orbimed, Google Ventures and 26 Others
- Latest Funding Round: Series C, Feb 16, 2021, $*****
- Highlight: Editors' Pick
Developer of genome sequencing-based diagnostics for infectious diseases. The company offers diagnostic solutions based on machine learning and genomics for infectious diseases. The assay includes Blood2Bac and BacDetect that uses whole-genome sequencing to identify both infecting species and drug resistance in bacterial infections.
Key facts about Day Zero Diagnostics
- Founded Year: 2016
- Location: Boston (United States)
- Stage: Series B
- Total Funding till date: $49M
- Employee Count: 48 as on Dec 31, 2024
- Investors: Triventures, Sands Capital and 10 Others
- Latest Funding Round: Series B, Sep 20, 2023, $*****
- Highlight: Editors' Pick
4. Kindstar
Provider of specialized medical testing services. It offers a comprehensive suite of tests across various medical specialties, including hematology, genetics, gynecology, infectious diseases, neurology, oncology, and routine testing. The company utilizes advanced technologies such as flow cytometry, PCR, sequencing, and mass spectrometry to deliver accurate and timely results. Its network of laboratories provides services to hospitals nationwide. The focus is on supporting healthcare professionals with high-quality diagnostic information.
Key facts about Kindstar
- Founded Year: 2003
- Location: Wuhan (China)
- Stage: Public
- Total Funding till date: $31M
- Employee Count: 11 as on Jul 01, 2024
- Investors: Mayo Clinic Business Accelerator, 5Y Capital and 9 Others
- Latest Funding Round: Series D, Nov 10, 2020, $*****
- Highlight: Public
5. XWPharma
XWPharma is a developer of drugs for treating neurological disorders like epilepsy, Parkinson's & others. It has developed XW10172 that is an investigational GABAB agonist that helps in the treatment of sleep disorders in Parkinson’s disease and narcolepsy. It also provides an XW10508 drug that is glutamatergic in nature and offers NMDA receptor inhibition. It helps in AMPA receptor activation for the treatment of Major depressive disorder (MDD) and chronic pain.
Key facts about XWPharma
- Founded Year: 2014
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $57.5M
- Employee Count: 16 as on Jul 01, 2024
- Investors: KTB Network, Johnson & Johnson Innovation and 12 Others
- Latest Funding Round: Series C, Sep 17, 2020, $*****
- Highlight: Editors' Pick
Panacea Venture's Year-on-Year Investment Trends
Panacea Venture has invested in 40 companies over the last 20 years, with an average of 2 new investments annually in the last 10 years. In 2025, it made 1 investment. Its most recent first time investment was in OutSee and most recent follow-on round was in Actym Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 1 | 0 | 1 |
2024 | 3 | 0 | 3 |
2023 | 0 | 1 | 1 |
2022 | 3 | 0 | 3 |
2021 | 2 | 1 | 3 |
2020 | 4 | 0 | 4 |
2019 | 2 | 0 | 2 |
2018 | 2 | 0 | 2 |
Panacea Venture's Investments by Stage
Panacea Venture has made 5 investments in Seed stage with an average round size of $37.5M, 5 investments in Series A stage with an average round size of $63.1M and 5 investments in Series B stage with an average round size of $41.4M.Stage of entry | No. of Investments |
|---|---|
Seed | 5 |
Series A | 5 |
Series B | 5 |
Post IPO | 1 |
Series C | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Panacea Venture's Investments by Sector
Panacea Venture has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Healthcare, Enterprise Applications and HealthTech. Notably, it has invested in 30 Enterprise (B2B) companies, 28 Tech companies, 3 Software companies and at least 2 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Life Sciences | 15 |
High Tech | 5 |
Healthcare | 4 |
Enterprise Applications | 3 |
HealthTech | 2 |
Others | 3 |
Note: We have considered here, only first round of investments
Panacea Venture's Investments by Geography
Panacea Venture has made most investments in China (7), followed by United States where it has made 7 investments.Country | No. of Investments |
|---|---|
China | 7 |
United States | 7 |
United Kingdom | 2 |
France | 1 |
Note: We have considered here, only first round of investments
Panacea Venture's recent investments
Panacea Venture has not made any investment in 2026 so far.Here are the most recent investments by Panacea Venture:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 24, 2025 | United Kingdom | Seed | 4597 | [+2] | |
Dec 31, 2024 | - | Seed | 8727 | ||
Dec 31, 2024 | China | Seed | 2214 | [+6] | |
Aug 21, 2024 | United States | Series B | 5092 | ||
Oct 18, 2023 | United States | Series A | 3056 |
IPOs and Publicly Listed companies in Panacea Venture's Portfolio
4 of Panacea Venture's portfolio companies have become public. Kindstar got listed on the Hong Kong Exchanges (HKG), in Jul 2021 at marketcap of $1.14B and Zhaoke Ophthalmology got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.16B.Here are Panacea Venture's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 16, 2021 | - | - | 4346 | |
Apr 29, 2021 | - | - | 5254 | |
Aug 26, 2005 | May 03, 2006 | Post IPO | 8703 | |
Aug 11, 1995 | - | - | 4198 |
Team profile of Panacea Venture
Panacea Venture has a team of 24 members including 12 Partners and 8 Venture Partners located in United States, China and 1 more location. Panacea Venture's team does not sit on the board of any company as of now.Here is a list of top team members in Panacea Venture:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Los Angeles | - | ||
Partner | United States | - | ||
Partner | Millbrae | - | ||
Partner | Shanghai | - | ||
Partner | San Francisco | - | ||
Partner | - | - | ||
Partner | - | - | ||
Partner | Shanghai | - | ||
Partner | Boston | - | ||
Partner | - | - |
Co-investors of Panacea Venture
Over the past 20 years, 131 investors have co-invested in Panacea Venture's portfolio companies. This includes funds and angels.
- Invested before Panacea Venture: Emerging Technology Partners, Threshold and 42 others have invested in rounds before Panacea Venture. There is 1 company where Emerging Technology Partners has invested before Panacea Venture and 1 company where Threshold has invested before Panacea Venture.
- Top Co-investors of Panacea Venture: 62 investors entered a company along with Panacea Venture. These include investors like Korea Investment Holdings (2 companies).
- Invested after Panacea Venture: A total of 25 investors have invested in Panacea Venture's portfolio after their investments. Top Investors include Duchenne (1 company), Gates Foundation (1 company) and Orbimed (1 company).
Recent News related to Panacea Venture
•
Kainova Therapeutics Secures $32M CAD to Accelerate Therapy DevelopmentBenzinga•Feb 10, 2026•Invest Quebec, , Turenne Groupe, Schroders Capital and 8 others
•
OutSee Closes £2.5M Seed Funding RoundFinSMEs•Jan 13, 2026•OutSee, Empirical Ventures, Kadmos Capital, Panacea Venture and 2 others
•
OutSee secures £1.8M to advance predictive genomics drug discovery with AI platform NomalyTech Funding News•Jun 24, 2025•OutSee, Ahren, Kadmos Capital, Empirical Ventures and 1 other
•
Orange Fail Pharmaceutical Complete nearly $ 50 million Pre-A round of financingEastmoney•Jan 02, 2025•VelaVigo, Panacea Venture, Shanghai Healthcare Capital, Delian Capital and 1 other
•
•
•
BHP appoints experienced financier to lead commercial finance offerInsider Media•Jun 17, 2024•BHP, Panacea Venture
•
•
•
Venture Firm, Cancer Center Start Antibody Biotech CompanyTechnology News and Literature•Sep 08, 2023•Panacea Venture, Mariana Oncology
